Pages that link to "Q28258516"
Jump to navigation
Jump to search
The following pages link to Potential pharmacological interventions in polycystic kidney disease (Q28258516):
Displaying 9 items.
- Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment (Q34194508) (← links)
- CFTR inhibitors (Q34553829) (← links)
- Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. (Q34627120) (← links)
- Renal tract malformations: perspectives for nephrologists (Q37150737) (← links)
- Clinical manifestations of autosomal recessive polycystic kidney disease (ARPKD): kidney-related and non-kidney-related phenotypes (Q38151554) (← links)
- Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models (Q40899081) (← links)
- Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease (Q42563582) (← links)
- Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease (Q43272350) (← links)
- Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months (Q46275214) (← links)